Cysview approved for cystoscopic detection of papillary bladder cancer

The FDA has approved Cysview (hexaminolevulinate HCl, from GE Healthcare), an optical imaging agent, for use in the cystoscopic detection of non-muscle-invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1).

For more information call (800) 658-0118 or visit www2.gehealthcare.com/portal/site/usen.